FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine and deals with a pharmaceutical composition for enhancing the efficiency of treatment of liver cancer by Sorafenib, with the said composition containing an anti-glypican 3-antibody as an active ingredient.
EFFECT: invention provides an improved anti-cancer effect and reduction of the side effect, in particular loss of the body weight.
14 cl, 9 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLYPICAN-3 ANTIBODY | 2005 |
|
RU2427588C2 |
| ANTIBODY TO GLYPICAN 3 | 2011 |
|
RU2611751C2 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| INTERLEUKIN (IL-17) ANTIBODY ANTAGONISTS FOR CANCER TREATMENT | 2007 |
|
RU2430110C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
| GPC3-TARGETED DRUG WHICH IS ADMINISTERED TO PATIENT SENSITIVE TO GPC3 DRUG-TARGETING THERAPY | 2013 |
|
RU2707882C2 |
| ANTI-GLYPICAN 3-ANTIBODY HAVING MODIFIED SUGAR CHAIN | 2005 |
|
RU2451030C2 |
| J591 MINIBODIES AND CYS-DIABODIES FOR TARGETED DELIVERY OF HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE | 2010 |
|
RU2673908C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
